当前位置: X-MOL 学术Immunol. Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Comparative study between human mesenchymal stem cells and etanercept as immunomodulatory agents in rat model of rheumatoid arthritis.
Immunologic Research ( IF 4.4 ) Pub Date : 2020-07-30 , DOI: 10.1007/s12026-020-09132-w
Heba El-Gendy 1 , Salah El-Deen Hawass 1 , Manal Awad 1 , Mona Ahmad Mohsen 1 , Maha Amin 2 , Hussein Abdelaziz Abdalla 3 , Samah Fouad 4 , Ahmed Lotfy 5
Affiliation  

To compare human adipose tissue mesenchymal stem cells (AT-MSCs) and etanercept as immunomodulatory agents for collagen-induced arthritis (CIA). CIA was induced by rats’ immunization with collagen type II (CII) in complete Freund’s adjuvant in days 0 and 7. Before the onset of CIA, prevention group received five doses of AT-MSCS intraperitoneally. After establishment of arthritis, rats received either five doses of AT-MSCs or phosphate-buffered saline (PBS) intraperitoneally or six doses of etanercept subcutaneously. Clinical and histopathological evaluation were performed in all groups; serum levels of tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), and anti-collagen II were assessed by enzyme-linked immunosorbent assay (ELISA). A total percent of autoreactive T and regulatory T (Treg) cells were quantified using spleen immune histochemical analysis. AT-MSCs were able to delay the onset of CIA, suppress the ongoing clinical and histopathological signs, decrease serum levels of TNF-α and anti-collagen type II, and downregulate the autoreactive T cells as etanercept. AT-MSCs were more potent in Treg cells upregulation, producing high serum levels of IL10. AT-MSCs might have a therapeutic effect in CIA via their potency in immune cell education, representing an effective new promising approach in rheumatoid arthritis in human.



中文翻译:

人间充质干细胞与依那西普在类风湿性关节炎大鼠模型中作为免疫调节剂的比较研究。

比较人脂肪组织间充质干细胞 (AT-MSC) 和依那西普作为胶原诱导性关节炎 (CIA) 的免疫调节剂。在第0天和第7天,大鼠用完全弗氏佐剂中的II型胶原(CII)免疫诱导CIA。在CIA发作前,预防组腹腔注射5剂AT-MSCS。建立关节炎后,大鼠腹膜内接受五剂 AT-MSCs 或磷酸盐缓冲盐水 (PBS),或皮下注射六剂依那西普。对所有组进行临床和组织病理学评估;通过酶联免疫吸附试验 (ELISA) 评估肿瘤坏死因子-α (TNF-α)、白细胞介素-10 (IL-10) 和抗胶原 II 的血清水平。使用脾免疫组织化学分析对自身反应性 T 和调节性 T (Treg) 细胞的总百分比进行量化。AT-MSCs 能够延迟 CIA 的发作,抑制正在进行的临床和组织病理学症状,降低血清 TNF-α 和抗 II 型胶原蛋白的水平,并像依那西普一样下调自身反应性 T 细胞。AT-MSCs 在 Treg 细胞上调中更有效,产生高血清水平的 IL10。AT-MSCs 可能通过其在免疫细胞教育中的效力对 CIA 产生治疗作用,代表了人类类风湿性关节炎的一种有效的新方法。AT-MSCs 在 Treg 细胞上调中更有效,产生高血清水平的 IL10。AT-MSCs 可能通过其在免疫细胞教育中的效力对 CIA 产生治疗作用,代表了人类类风湿性关节炎的一种有效的新方法。AT-MSCs 在 Treg 细胞上调中更有效,产生高血清水平的 IL10。AT-MSCs 可能通过其在免疫细胞教育中的效力对 CIA 产生治疗作用,代表了人类类风湿性关节炎的一种有效的新方法。

更新日期:2020-07-31
down
wechat
bug